Excellent start to Plenary II Should we borrow SGLT2i and DPP4i use from endocrine? SLE pts who initiated SGLT2 or DPP4: lower risk of MACE and renal progression @RheumNow #ACR23 Abs#1579 https://t.co/RsaWuetyft

Glucocorticoids-free zone in SLE? For over 70 years, glucocorticoids, (GC) have been a part of standard therapy in SLE. They are classically used to not only induce remission or treat an acute flare, but also as maintenance therapy. #ACR23 https://t.co/sfRhNj6OpZ https://t.co/k6VoG5lKO7

• Glucocorticoids-free zone in SLE? | RheumNow

Patients with autoimmnue diseases have a high maternal and fetal complication rate! Abst 1003 #ACR23 @RheumNow https://t.co/pnvvBUN2JG

Pt w/ refractory SCLE, wants to get pregnant. Dr. Petri's approach is: counsel patient and review meds (e.g PPI's can induce SCLE). She also asks: Where's your hat and sunblock? Get HCQ blood levels b/f starting anifrolumab or belimumab #ACR23 @rheumnow #MeetExpert

Difficult SLE skin dse? Dr. Mosca reminds us to engage pts in the treatment process including adherence to preventive measures & lifestyle mods (sun protection, smoking) Other considerations: + antimalarials early use of newer tx? - Anifrolumab #ACR23 @RheumNow https://t.co/kz8YfcBB2d

When to use #belimumab and when to use #voclosporin? Dr. Dall'Era does the following: Belimumab: GFR<45, low proteinuria, extrarenal dz, pt factors Voclosporin: GFR>45 w/o sig chronicity, high level proteinuria (3+g/), pt preference for oral #ACR23 #MeetExpert @rheumnow https://t.co/0SXRBtChfk

"Get rid of partial response. Why would you want to see an oncologist who say I can get risk part of your cancer? Wouldn't you want to get rid of the whole cancer!" - Dr. M Petri on how we should view lupus nephritis #ACR23 @rheumnow #MeetExpert

Proof of concept for cCAR BCMA CD19 - safely eliminated all autoabs, reset B cell/humoral immune system, & delivered long-term, med-free remission in 1 dose in LN and SLE. More studies needed! #ACR Abs 1493 @rheumnow https://t.co/sT68cN3TKe

UTSW Dallas study: Health literacy may be essential limiting factor for families w/ children w/ SLE. Other critical barriers to patient care include food security and living costs such as transportation, housing, and utilities. #ACR23 Abs #1029 https://t.co/jtnIgLZQfC @rheumnow https://t.co/A1zr8quSdd

LV mass higher in pts with SLE nephritis.Nested case-control study 48 SLE pts +/- LN. LV mass higher w/LN (66.9 g/m2) vs pts w/o LN (54.8 g/m2, p=0.035). Higher LV mass may increase risk for CV events as CHF, arrhythmias and CV mortality. @RheumNow #ACR23 abst#1447

Real World SLE Rx patterns from the SPOCS cohort. 70+% IFN high, 81% on antimalarials, 21% biologics, and 55% IS, 65% GCs. High IFN pts had more IS and steroid use. 45+% still on GCs at 12 months despite avail of new therapeutics @RheumNow #ACR23 abst#0592

Vasc Events in Danish Cohort: 3178 SLE pts matched to 60K controls. MI in SLE 2.9% vs 1.4%, cerebrovascular dz 7% vs 2.7%, & PVD 5.5% vs 1.4%. IRR ranged 1.7-7.6. Female SLE pts had 3-5X risk for CVE, Male pts 6-8X risk. @RheumNow #ACR23 abst#1442 https://t.co/PapDiJ0shJ

Obintuzumab in Lupus Nephritis Researchers found that treatment with obinutuzumab was superior to placebo for preserving kidney function and preventing flares in patients with lupus nephritis. https://t.co/Sbh6k6XKjz https://t.co/aDbLUh7WtM

• Obintuzumab in Lupus Nephritis | RheumNow

ABS0122 at #ACR23 ⭐️Risk of acute MI, stroke & death signif ⬆️ among RA/SLE pts w/ depress, anxiety, &/or PTSD vs w/o both RA/SLE ➡️U.S. pts: 3825 RA, 1862 SLE --> 1790 w/ above mental health dz, no prior CVD ➡️HR 1.28 after adjusting for🚬, obesity, & comorbidities @RheumNow https://t.co/sXMFtaKmYB

TM02 @ #ACR23: 19yo F w/ SLE p/w 1w DOE PMHx: SLE (malar, LN, AIHA, ITP) on HCQ x 10yrs Dx? HCQ-induced CM (curvilinear bodies, vacuolar degen) ⭐️RF for HCQ-induced cardio-toxicity: - older age, F - HCQ > 10 yrs, ⬆️ daily dose - hx of cardiac dz - renal insuffic @RheumNow https://t.co/GgzB2Chgra